1134191-22-2

Basic information

• Product Name: 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate
• Synonyms: 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate
• CAS NO: 1134191-22-2
• Molecular Weight: 726.923
• Mol File: 1134191-22-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate(1134191-22-2)
• EPA Substance Registry System: 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate(1134191-22-2)

Safety Data

• Hazardous Substances Data: 1134191-22-2(Hazardous Substances Data)

Upstream product

• 927690-90-2 N-{1-[3-(2-ethoxyphenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}butyroamide 
• 104-46-1 anethole 
• 18637-00-8 2-ethoxy-benzamidine hydrochloride 
• 6609-57-0 2-ethoxybenzonitrile 
• 1134191-30-2 C₂₅H₃₄N₆O₆S 
• 224789-26-8 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulfonic acid chloride 
• 224789-21-3 2-(2-ethoxyphenyl)-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 59875-04-6 2-butyrylaminopropionic acid 
• 532-11-6 anethole trithione 
• 18274-81-2 desmethyl anethole trithione 
• 1134191-27-7 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetic acid 

Relevant articles and documents

NEW AGENTS FOR THE TREATMENT OF THE LOW URINARY TRACT DYSFUNCTIONS

The present invention relates to novel compounds that are derivatives of 5 -phosphodiesterase inhibitors that comprise in their formula a polysulfurated group and that are useful for treating dysfunctions of low urinary tract such as incontinence, benign prostatic hyperplasia and erectile dysfunction.